OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network

Rhea-AI Summary

OptimizeRx (Nasdaq: OPRX) announced four new partner agreements on Dec. 17, 2025 that expand its point-of-care (POC) network, deepen exclusivity with key platforms, and increase total National Provider Identifier reach. Together the additions and renewals raise OptimizeRx’s unique NPI reach by 37%.

Key deals include an exclusive multi-year agreement with a high-demand e-prescribing platform, a new point-of-discharge partnership that extends access when treatment plans are finalized, and multi-year renewals with two top-performing EHR/eRx partners that secure premium inventory and greater visibility into future channel revenue.

Positive

• Unique NPI reach increased by 37%
• Exclusive multi-year eRx agreement secures premium inventory
• New point-of-discharge partner adds clinical-workflow reach
• Multi-year renewals strengthen relationships with top EHR/eRx partners

Negative

• None.

Key Figures

NPI reach increase 37% Increase in unique National Provider Identifier reach from new partners

New partner agreements 4 Total new and renewal agreements announced in this release

New channel partners 2 Additional channel partners expanding point-of-care footprint

Market Reality Check

$12.74 Last Close

Volume Volume 204,375 is about 0.87x the 20-day average of 234,890, indicating below-normal activity pre-announcement. normal

Technical Shares at $12.77 were trading below the 200-day MA of $13.78 ahead of the expansion news.

Peers on Argus 1 Up

Pre-news, OPRX was down 3.11% while close peers showed mixed moves: SPOK +1.14%, NRC +2.56%, SY +2.09%, TBRG -1.29%, DH -0.43%. Scanner momentum flagged only MNDR at +10.19% with no news, suggesting today’s announcement is more stock-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 06	Q3 2025 earnings	Positive	-1.1%	Strong Q3 revenue and profit growth with raised 2025 and 2026 guidance.
Oct 30	Earnings call notice	Neutral	-4.6%	Announcement of upcoming Q2 2025 earnings call and access details.
Oct 20	Q3 call scheduling	Neutral	+3.8%	Scheduled Q3 2025 results conference call and replay information.
Sep 10	Conference participation	Neutral	-1.3%	Participation in Lake Street Capital Best Ideas Growth investor conference.
Sep 09	Lamar partnership	Positive	-1.3%	Strategic Lamar partnership using Micro-Neighborhood Targeting for OOH campaigns.

Pattern Detected

Positive fundamental and partnership news has previously seen muted or negative next-day reactions, while neutral event announcements have produced mixed moves.

Recent Company History

Over the last six months, OptimizeRx has combined partnership expansion with improving fundamentals. A Sept 9 partnership with Lamar focused on targeted out-of-home campaigns, while conference appearances on Sept 10 and Oct 20 supported investor outreach. The Nov 6 Q3 2025 results showed revenue and profitability growth plus higher guidance, yet the stock slipped modestly. Today’s point-of-care network expansion adds to this pattern of strategic growth initiatives not always mirrored by immediate price strength.

Market Pulse Summary

This announcement focuses on expanding OptimizeRx’s point-of-care network through four new and renewed partnerships, including exclusive deals and two new channel partners. Management highlights a 37% increase in unique NPI reach and greater access at e-prescribing and discharge points. In context of recent revenue growth and guidance raises, the news underscores a strategy of deepening workflow integration. Investors may watch future disclosures for evidence that broader reach converts into sustained channel revenue and margins.

Key Terms

point-of-care medical

"expand the Company’s in-workflow point-of-care (POC) network, fortify its long-term"

"Point-of-care" refers to the location where immediate decision-making or actions happen, often involving the direct delivery of services or results. In healthcare, it describes tests or treatments performed directly at the patient's side, rather than in a distant laboratory. For investors, understanding "point-of-care" highlights the convenience, speed, and potential growth opportunities of services or products that bring solutions directly to the user or patient.

electronic health record medical

"two of the Company’s highest-performing electronic health record (EHR) and eRx partners"

A digital version of a patient’s medical chart that collects health information — diagnoses, medications, lab results, imaging and doctors’ notes — in one place so authorized clinicians can view and update it. For investors, electronic health records matter because they drive revenue and costs for companies that build, sell or rely on them, influence how quickly care is delivered, and create opportunities (and risks) tied to data access, software updates, regulation and patient privacy. Think of it as an online file cabinet for health that affects how the healthcare system runs and spends money.

e-prescribing medical

"exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously"

E-prescribing is the electronic transmission of a medical prescription from a healthcare professional to a pharmacy using digital systems rather than paper or fax. Think of it like sending a secure, digital grocery list that goes straight to the store: it speeds up fulfillment, reduces mistakes, and creates data that can be tracked. For investors, adoption and quality of e-prescribing systems can affect healthcare costs, pharmacy sales, regulatory compliance, and the competitive position of health IT and pharmacy businesses.

national provider identifier medical

"and increase total National Provider Identifier (NPI) reach."

A national provider identifier (NPI) is a unique ten-digit number assigned to healthcare professionals and organizations for use in administrative and billing transactions within the United States healthcare system. For investors, NPIs matter because they link payments, claims and provider credentials to specific entities—like a Social Security number for medical providers—making it easier to verify revenue sources, assess network size and check compliance and billing risk in healthcare-related investments.

healthcare professionals medical

"helping life sciences companies reach and engage healthcare professionals (HCPs) and patients"

Individuals trained and licensed to provide medical care, advice, or treatment—such as physicians, nurses, pharmacists, therapists and physician assistants—who evaluate patients, prescribe or administer therapies, and make care decisions. Investors watch healthcare professionals like gatekeepers and frontline users because their prescribing patterns, adoption of new treatments or devices, and professional opinions directly affect demand, reimbursement decisions and a company’s sales prospects.

AI-generated analysis. Not financial advice.

Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37%

WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company’s in-workflow point-of-care (POC) network, fortify its long-term competitive position, and increase total National Provider Identifier (NPI) reach.

The newly executed agreements include:

• An exclusive, multi-year agreement with a high-demand e-prescribing (eRx) platform previously available only through a competitive network
• A new partnership that extends the Company’s presence into the point-of-discharge setting
• Multi-year renewals with two of the Company’s highest-performing electronic health record (EHR) and eRx partners—one of which establishes an exclusive partnership
  
  

Together, these agreements significantly expand OptimizeRx’s strategic footprint and reinforce the Company’s leadership in the POC marketing landscape.

With the addition of two new channel partners, OptimizeRx increases its unique NPI reach by 37%. The new partners include an eRx platform that was previously part of a competitive network, and a health systems access partner that reaches HCPs when treatment plans and patient instructions are finalized. The latter partner also provides OptimizeRx with reach into an extended network of EHR platforms, broadening OptimizeRx clients’ access to healthcare providers directly in the clinical workflow.

The renewals strengthen our partnerships with long-term, top-performing EHR and eRx platforms and secure exclusive access to premium inventory. They also increase visibility into future channel revenue, based on the partners’ historical track record of strong utilization, consistent performance, and high ROIs for life sciences brands.

“By deepening relationships with proven, high-value partners and adding exclusive access to large-scale platforms that were previously outside our network, we continue to position the Company for sustained, profitable growth, driven by our clients’ ability to reach a larger audience of relevant providers,” said Steve Silvestro, Chief Executive Officer, OptimizeRx. “Life sciences manufacturers continue to recognize the value of in-workflow engagement for driving brand awareness and conversion. Our network scale, technology assets, and strategic partnerships place us in a strong position to capture growing demand and deliver measurable results for our clients. We believe the steps we are taking today will meaningfully enhance the value we deliver to our clients.”

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life sciences brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on LinkedIn or X, or visit www.optimizerx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expected", "will", "believe", "could", "may", "should" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to expanding OptimizeRx’s strategic footprint and reinforcing the Company’s leadership in the POC marketing landscape, securing or maintaining exclusive access to premium inventory, increasing visibility into future channel revenue, positioning OptimizeRx for sustained, profitable growth, increasing clients’ ability to reach a greater portion of relevant HCPs, driving brand awareness and conversion, and capturing growing demand and delivering measurable results for clients. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

OptimizeRx Contact
Jennifer Dinkel, VP Marketing
jdinkel@optimizerx.com

Press Inquiries
Matter Communications
optimizerx@matternow.com

FAQ

What did OptimizeRx (OPRX) announce on December 17, 2025?

OptimizeRx announced four partner agreements that expand its POC network and increase unique NPI reach by 37%.

How much did OptimizeRx increase its NPI reach with the new partnerships?

The company reported a 37% increase in unique National Provider Identifier reach.

Which types of partners did OptimizeRx add in the Dec. 17, 2025 announcement?

New partners include an exclusive multi-year e-prescribing (eRx) platform, a point-of-discharge partner, and renewals with two EHR/eRx platforms.

What does the exclusive eRx agreement mean for OPRX shareholders?

The exclusive multi-year eRx agreement secures access to premium inventory that could increase ad visibility and campaign reach for clients.

Do the renewals affect OptimizeRx’s revenue visibility?

Yes; the multi-year renewals increase visibility into future channel revenue based on partners’ historical utilization and performance.

Will the new point-of-discharge partner change where OptimizeRx reaches healthcare providers?

Yes; it extends OptimizeRx’s access into the point-of-discharge setting where treatment plans and patient instructions are finalized.